Research on Traditional Chinese Medicine (TCM) Clinical Treatment of the Acute Episode of Bronchial Asthma.

NCT ID: NCT01293734

Last Updated: 2011-02-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

360 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bronchial asthma is a common disease and frequently encountered disease of respiratory apparatus. It has very complex mechanism and multiple inducing factors. This study will focus on a new Chinese therapy on Bronchial asthma, analyzing the treatment mechanism of internal and external use, based on Traditional Chinese Medicine (TCM) theory and clinical practice. The study will also investigate the efficacy of the Chinese drugs and treatments on Bronchial asthma, and provide an effective therapy for this disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchial Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cold type

To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in cold type

Group Type EXPERIMENTAL

warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum

Intervention Type OTHER

warming lung and relieving asthmatic granule:once 1 bag, 3 times a day. Securing origin and warming lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day

heat type

To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in heat type.

Group Type EXPERIMENTAL

clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum

Intervention Type OTHER

clearing lung and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and clearing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day

Asthenia type

To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in Asthenia type.

Group Type EXPERIMENTAL

securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum

Intervention Type OTHER

securing origin and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and nourishing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day

Western medicine control group

Group Type ACTIVE_COMPARATOR

Theophylline Sustained-release Tablets and budesonide suspension

Intervention Type DRUG

Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum

warming lung and relieving asthmatic granule:once 1 bag, 3 times a day. Securing origin and warming lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day

Intervention Type OTHER

clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum

clearing lung and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and clearing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day

Intervention Type OTHER

securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum

securing origin and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and nourishing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day

Intervention Type OTHER

Theophylline Sustained-release Tablets and budesonide suspension

Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 to 65 years old;
* Patients with mild-to-moderate bronchial asthma on attacking stage;
* Without cardiopulmonary or other complications;
* To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome differentiation;
* Informed consent form is required to be signed.

Exclusion Criteria

* Older than 65 years or younger than 18 years old;
* Pregnant woman or suckling period woman;
* Patients combine serious primary disease in liver, renal, cardiovascular and cerebrovascular, hemopoietic system diseases,or psychosis.
* Severe levels of disease is between severe and critical extent. Combine Pulmonary Heart Disease or respiratory failure;
* Irritable the physique, or allergic to the given composition of drugs in this research;
* Patients who are in the process of other clinical research.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shenyang Huanggu District Central Hospital

UNKNOWN

Sponsor Role collaborator

Benxi City hospital of Chinese medicine

OTHER

Sponsor Role collaborator

Anshan Central Hospital

OTHER

Sponsor Role collaborator

Liaoning University of Traditional Chinese Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

No.2 Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

sygzwu

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Idiopathic Pulmonary Fibrosis Cohort of TCM
NCT07162870 NOT_YET_RECRUITING